Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMPGet Rating) from a hold rating to a sell rating in a research note published on Wednesday, Zacks.com reports.

According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “

Shares of ARMP opened at $4.25 on Wednesday. Armata Pharmaceuticals has a 52 week low of $2.82 and a 52 week high of $6.49. The stock has a market capitalization of $153.47 million, a P/E ratio of -4.25 and a beta of 1.06.

Armata Pharmaceuticals (NYSEAMERICAN:ARMPGet Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Armata Pharmaceuticals had a negative net margin of 569.21% and a negative return on equity of 75.90%. Equities analysts forecast that Armata Pharmaceuticals will post -0.92 earnings per share for the current year.

A number of large investors have recently modified their holdings of ARMP. Susquehanna International Group LLP acquired a new position in Armata Pharmaceuticals in the 4th quarter valued at approximately $66,000. Dimensional Fund Advisors LP acquired a new position in Armata Pharmaceuticals in the 4th quarter valued at approximately $72,000. BlackRock Inc. increased its position in Armata Pharmaceuticals by 928.0% in the 3rd quarter. BlackRock Inc. now owns 20,571 shares of the company’s stock valued at $74,000 after acquiring an additional 18,570 shares during the period. Northern Trust Corp acquired a new position in Armata Pharmaceuticals in the 1st quarter valued at approximately $95,000. Finally, Vanguard Group Inc. increased its position in Armata Pharmaceuticals by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 273,150 shares of the company’s stock valued at $1,335,000 after acquiring an additional 10,400 shares during the period. 4.30% of the stock is owned by institutional investors and hedge funds.

Armata Pharmaceuticals Company Profile (Get Rating)

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.

Featured Stories

Get a free copy of the Zacks research report on Armata Pharmaceuticals (ARMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.